Three overlapping frameworks — none of which replaces the others

FDA SaMD clearance, EU MDR conformity assessment, and EU AI Act registration are independent obligations. Achieving one does not satisfy the others. Companies selling AI-enabled medical devices in both the US and EU must complete all three separately.

What Counts as AI in a Medical Device?

The regulatory scope is broader than most teams realise. AI in a medical device context includes:

Diagnostic AI: Algorithms that analyse imaging (X-ray, MRI, pathology slides) to detect conditions
Predictive clinical AI: Models predicting patient deterioration, sepsis risk, readmission likelihood
Treatment planning AI: Radiotherapy planning, drug dosing recommendation systems
Triage and monitoring AI: Real-time patient monitoring with automated alerts
Administrative clinical AI: AI that automates clinical documentation with downstream patient safety implications

Both the FDA and EU regulators distinguish between locked algorithms (fixed after training) andadaptive/continuous learning algorithms (update themselves post-deployment). Adaptive algorithms face stricter requirements because their behaviour changes over time.

Framework 1: FDA Software as a Medical Device (SaMD)

In the US, AI that meets the definition of a medical device requires FDA review before market entry. The FDA's framework for AI-enabled devices builds on its Software as a Medical Device (SaMD) guidance.

Does Your AI Need FDA Clearance?

The FDA applies the Device Software Functions (DSF) framework. Not all health software is regulated. The key test: does the software function to diagnose, treat, prevent, or cure a condition? If yes, it likely requires clearance.

Exempt from FDA review

General wellness apps (step counters, general stress management), administrative hospital software, electronic health records without clinical decision making

NSTC — Non-Device Software Functions

Software intended for administrative support, maintaining records, transferring data — not making clinical decisions

Requires FDA clearance (510k) or approval (PMA)

AI diagnosing diabetic retinopathy, AI detecting stroke from CT scans, AI recommending medication doses, AI predicting sepsis risk from vitals

FDA Clearance Pathways for AI Devices

Pathway	When Used	Timeline	Cost
510(k) Premarket Notification	AI similar to a legally marketed predicate device	3–12 months	$20,000–$100,000
De Novo Request	Novel AI with no predicate; low-to-moderate risk	9–18 months	$50,000–$200,000
Premarket Approval (PMA)	High-risk AI (Class III); life-sustaining	18–48 months	$200,000–$2M+
Breakthrough Device	Priority review for serious conditions; 25% faster	Varies	FDA fee waiver possible

FDA SaMD Documentation Requirements

The FDA expects AI device submissions to include:

Algorithm description: Architecture, inputs, outputs, intended use, intended user population

Training data description: Source, demographic representation, preprocessing, labelling methodology, train/test splits

Performance testing: Sensitivity, specificity, AUC, performance by demographic subgroup, comparison to clinical gold standard

Cybersecurity documentation: Threat model, security controls, patch management process per FDA cybersecurity guidance

Change control protocol: For adaptive AI: predetermined change control plan specifying which types of updates require new submission

Human factors validation: Evidence that clinician users can correctly use the AI output in practice

Framework 2: EU Medical Device Regulation (EU MDR)

In the EU, AI embedded in medical devices must comply with EU MDR (2017/745). MDR replaced the older Medical Device Directive (MDD) and carries significantly stricter requirements, particularly for software.

Under MDR, AI software qualifies as a medical device if it performs a medical purpose — diagnosis, monitoring, prediction, prognosis, treatment, or alleviation of disease. Software that merely stores or displays data without clinical decision-making does not qualify.

MDR Classification and Conformity Assessment

MDR Class	AI Examples	Conformity Assessment
Class I	Fitness tracking with health indicators; general wellness AI	Self-certification (Declaration of Conformity)
Class IIa	AI analysing non-life-threatening imaging; wound assessment AI	Notified Body involvement required
Class IIb	AI for monitoring vital signs in hospital; AI-assisted surgical guidance	Full quality management system audit by Notified Body
Class III	AI diagnosing life-threatening conditions; brain/cardiac AI with treatment implications	Full technical dossier review; design examination by Notified Body

Notified Bodies are the independent certification organisations that review Class IIa+ medical devices. With EU MDR, the number of Notified Bodies dropped dramatically (from 80+ under MDD to ~35), creating a significant backlog. Budget 12–24 months for Notified Body review for Class IIb/III devices.

MDR Technical Documentation for AI

EU MDR Annex II requires technical documentation covering (among other items):

Device description, intended purpose, and intended users
Design and manufacturing information (including software lifecycle per IEC 62304)
General safety and performance requirements (Annex I) compliance
Benefit-risk analysis
Post-market clinical follow-up (PMCF) plan
For AI: algorithm validation, training data characteristics, performance by clinical subgroup

Framework 3: EU AI Act — Healthcare AI as High-Risk

The EU AI Act classifies healthcare AI as high-risk through two entirely separate legal mechanisms — only one of which is Annex III:

Annex III, Category 5 (the access-to-essential-services route, split by sub-point — web-verified against the Regulation's own text): 5(a) covers AI used by or on behalf of public authorities to evaluate eligibility for essential public assistance benefits and services, including healthcare services, and to grant/reduce/revoke them (e.g. AI deciding Medicaid-style coverage eligibility); 5(d) specifically covers emergency-services dispatch and "emergency healthcare patient triage systems" — this is the correct sub-point for AI triaging patients, not 5(a). Neither sub-point covers diagnostic or treatment-recommendation AI itself.
Article 6(1) + Annex I (the product-safety/MDR route — this is the one that applies to most AI-enabled medical devices, including diagnostic and clinical decision-support AI): AI embedded in a product already regulated under EU MDR or IVDR that requires third-party conformity assessment is automatically deemed high-risk under the AI Act, with AI Act conformity-assessment requirements folded into the existing MDR/IVDR notified-body procedure under Article 43(3) — not a separate Annex III classification.

EU AI Act Requirements for High-Risk Healthcare AI

EU AI Act database registration: Register in the EU-wide public database before placing on the market. Deployers must also register when required.

Risk management system: Continuous risk management throughout the AI system lifecycle — not just at deployment. Annual review minimum.

Data governance: Training and testing data must meet quality criteria. Bias assessment required across patient demographics (age, sex, ethnicity, comorbidities).

Technical documentation (Article 11): Extensive documentation of system design, training methodology, performance metrics, known limitations.

Human oversight: Technical measures enabling clinicians to monitor, intervene, and override AI outputs. Clinician must be able to reject AI recommendations.

Accuracy, robustness, cybersecurity: High-risk healthcare AI must meet performance thresholds and cannot degrade in real-world deployment without alert.

CE marking (via MDR conformity): For AI embedded in EU MDR devices, CE marking for the device satisfies some AI Act requirements — but additional AI Act documentation still required.

Where FDA, EU MDR, and EU AI Act Overlap

Requirement	FDA	EU MDR	EU AI Act	Synergy?
Technical documentation	✓	✓	✓	Partial overlap — FDA 510k dossier ≠ EU MDR technical file ≠ AI Act Article 11
Training data description	✓	✓	✓	Strong overlap — document once, reference across all three
Performance testing	✓	✓	✓	Strong overlap — same clinical validation data used for all three
Post-market monitoring	✓	✓	✓	Partial overlap — different reporting channels (FDA MedWatch/MDR vs EU EUDAMED vs the EU AI Act's national market surveillance authorities under Art. 72/73 — not ESMA, which is the EU's securities regulator and unrelated to the AI Act)
Human oversight requirement	✓	✓	✓	Strong overlap — one set of override controls satisfies all three
Change management	✓	Limited	✓	FDA PCCP and AI Act lifecycle process align; EU MDR has less formal change control
Registry/database registration	—	EUDAMED	EU AI Act DB	Different registries — both required for EU market

Practical Compliance Timeline for Healthcare AI Manufacturers

For a company building AI diagnostic software for both the US and EU market, a realistic compliance timeline:

Months 1–3

Design and architecture

Define intended use precisely (this determines FDA pathway + MDR class + EU AI Act category). Build technical documentation infrastructure from day one — retro-fitting is expensive.

Months 3–9

Clinical validation study

Run prospective validation with appropriate patient population diversity. Document training/test data provenance. Results feed FDA submission, MDR technical file, and EU AI Act documentation simultaneously.

Months 6–12

FDA pre-submission meeting

Request Q-sub meeting with FDA to agree on submission pathway and acceptance criteria before spending 6 months preparing the wrong package.

Months 9–18

FDA 510(k) or De Novo submission

Prepare and submit to FDA. Typical review timeline 3–12 months after submission. Continue EU preparation in parallel.

Months 12–24

EU MDR Notified Body engagement

Engage Notified Body early — they have 12–18 month backlogs for Class IIb/III. Submit technical dossier. Parallel: register in EUDAMED.

Months 15–24

EU AI Act registration

Register in EU AI Act database. Complete risk management documentation. Establish post-market monitoring system per AI Act lifecycle requirements.

Key Risks Healthcare AI Companies Underestimate

Scope creep triggers reclassification: Adding a new clinical indication or patient population mid-development can trigger a higher risk class — requiring a more expensive pathway. Lock your intended use before investing in validation.
Notified Body backlog: With only ~35 EU MDR-designated Notified Bodies, lead times are 12–24 months. Start engagement early or miss your EU launch window.
Adaptive algorithm change control: Both FDA (PCCP) and EU AI Act require pre-defined processes for how the AI can change after clearance. Design this process before submission — retrofitting it is complex.
Sub-group performance gaps: Regulators increasingly scrutinise AI performance across demographic subgroups (age, sex, ethnicity). Insufficient diversity in validation data is a leading cause of FDA submission rejections.
Post-market surveillance obligations: Both FDA (MDR adverse event reporting) and EU MDR (PMCF) require ongoing post-market monitoring. This is not a one-time activity — budget for it operationally.

Track Your Healthcare AI Compliance Status

Aegis Firma maps your AI systems against FDA, EU MDR, and EU AI Act requirements simultaneously — so you can see what is complete, what is outstanding, and what needs updating as regulations evolve.

Start Your Assessment

AI Compliance for Healthcare Devices: FDA SaMD, EU MDR, and EU AI Act